journal
https://read.qxmd.com/read/38033284/bosutinib-in-resistant-and-intolerant-pediatric-patients-with-chronic-phase-chronic-myeloid-leukemia-results-from-the-phase-i-part-of-study-itcc054-cog-aaml1921
#1
JOURNAL ARTICLE
Erica Brivio, Edoardo Pennesi, Marieke E Willemse, Alwin D R Huitema, Yilin Jiang, Harm D R van Tinteren, Vincent H J van der Velden, Berna H Beverloo, Monique L den Boer, Lukas A J Rammeloo, Chad Hudson, Nyla Heerema, Karey Kowalski, Huadong Zhao, Luke Kuttschreuter, Francisco J Bautista Sirvent, Andrew Bukowinski, Carmelo Rizzari, Jessica Pollard, Laura Murillo-Sanjuán, Matthew Kutny, Sara Zarnegar-Lumley, Michele Redell, Stacy Cooper, Yves Bertrand, Arnaud Petit, Julie Krystal, Markus Metzler, Donna Lancaster, Jean-Pierre Bourquin, Jayashree Motwani, Inge M van der Sluis, Franco Locatelli, Michael E Roth, Nobuko Hijiya, Christian M Zwaan
PURPOSE: Bosutinib is approved for adults with chronic myeloid leukemia (CML): 400 mg once daily in newly diagnosed (ND); 500 mg once daily in resistant/intolerant (R/I) patients. Bosutinib has a different tolerability profile than other tyrosine kinase inhibitors (TKIs) and potentially less impact on growth (preclinical data). The primary objective of this first-in-child trial was to determine the recommended phase II dose (RP2D) for pediatric R/I and ND patients. PATIENTS AND METHODS: In the phase I part of this international, open-label trial (ClinicalTrials...
November 30, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/38033283/inflammatory-tongue-conditions-and-risk-of-oral-tongue-cancer-among-the-us-elderly-individuals
#2
JOURNAL ARTICLE
Joseph E Tota, Eric A Engels, Mark W Lingen, Nishant Agrawal, Alexander R Kerr, Zachary S Zumsteg, Li C Cheung, Hormuzd A Katki, Christian C Abnet, Anil K Chaturvedi
PURPOSE: The incidence of oral tongue cancers has increased since the 1980s among US men and women for unknown reasons. We investigated associations of inflammatory tongue conditions with risk of cancers of the oral tongue, other oral cavity, and oropharynx among the US elderly individuals (age 65 years or older). METHODS: We conducted a case-control study (2,534 oral tongue cancers, 6,832 other oral cavity cancers, 9,373 oropharyngeal cancers, and 200,000 controls) within the SEER-Medicare data set (1992-2013)...
November 30, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/38033277/first-line-dual-immunotherapy-a-treatment-option-in-first-line-metastatic-non-small-cell-lung-cancer-are-we-ready-to-use-it
#3
JOURNAL ARTICLE
Dipesh Uprety, Jordi Remon, Solange Peters
No abstract text is available yet for this article.
November 30, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/38016094/gosses-and-the-dalmatian-puppy
#4
JOURNAL ARTICLE
Zvi Symon
No abstract text is available yet for this article.
November 28, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/38011605/chimeric-antigen-receptor-car-t-cell-products-for-pediatric-cancers-why-alternative-development-paths-are-needed
#5
JOURNAL ARTICLE
Claudia Rossig, Andrew D Pearson, Gilles Vassal, Nicole Scobie, Nick Bird, Patricia Blanc, H Josef Vormoor, Friso G Calkoen, Franco Locatelli, Francesca Del Bufalo, Susana Rives, Elad Jacoby, Adriana Balduzzi, Jean-Pierre Bourquin, André Baruchel
No abstract text is available yet for this article.
November 27, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37992266/dna-mutational-profiling-in-patients-with-colorectal-cancer-treated-with-standard-of-care-reveals-differences-in-outcome-and-racial-distribution-of-mutations
#6
JOURNAL ARTICLE
Federico Innocenti, Wancen Mu, Xueping Qu, Fang-Shu Ou, Omar Kabbarah, Charles David Blanke, Alan P Venook, Heinz-Josef Lenz, Naim U Rashid
PURPOSE: CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab with chemotherapy. We aimed to discover novel mutated genes associated with prognosis and differential response to therapy with the biologics. METHODS: Primary tumor DNA from 548 patients was sequenced using FoundationOne. The effect of mutated genes and mutations on overall survival (OS) was tested adjusting for microsatellite instability status, BRAF V600E, all RAS mutations, arm, sex, and age...
November 22, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37992261/predictive-value-of-minimal-residual-disease-for-efficacy-of-rituximab-maintenance-in-mantle-cell-lymphoma-results-from-the-european-mantle-cell-lymphoma-elderly-trial
#7
JOURNAL ARTICLE
Eva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre, Linmiao Jiang, Stephan Stilgenbauer, Ursula Vehling-Kaiser, Gilles Salles, Catherine Thieblemont, Hervé Tilly, Stefan Wirths, Pierre Feugier, Kai Hübel, Christian Schmidt, Vincent Ribrag, Johanna C Kluin-Nelemans, Martin Dreyling, Christiane Pott
PURPOSE: The outcome of older patients with mantle cell lymphoma (MCL) has improved by the introduction of immunochemotherapy, followed by rituximab (R)-maintenance. Assessment of minimal residual disease (MRD) represents a promising tool for individualized treatment decisions and was a prospectively planned part of the European MCL Elderly trial. We investigated how MRD status influenced the efficacy of R-maintenance and how MRD can enable tailored consolidation strategies. PATIENTS AND METHODS: Previously untreated patients with MCL age 60 years or older have been randomly assigned to R versus interferon-alpha maintenance after response to rituximab, fludarabine, cyclophosphamide (R-FC) versus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP)...
November 22, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37988648/efficacy-and-safety-of-disitamab-vedotin-in-patients-with-human-epidermal-growth-factor-receptor-2-positive-locally-advanced-or-metastatic-urothelial-carcinoma-a-combined-analysis-of-two-phase-ii-clinical-trials
#8
JOURNAL ARTICLE
Xinan Sheng, Lin Wang, Zhisong He, Yanxia Shi, Hong Luo, Weiqing Han, Xin Yao, Benkang Shi, Jiyan Liu, Changlu Hu, Ziling Liu, Hongqian Guo, Guohua Yu, Zhigang Ji, Jianming Ying, Yun Ling, Shiying Yu, Yi Hu, Jianming Guo, Jianmin Fang, Aiping Zhou, Jun Guo
PURPOSE: To evaluate the efficacy and safety of disitamab vedotin (DV, RC48-ADC), a novel humanized anti-human epidermal growth factor receptor 2 (HER2) antibody conjugated with monomethyl auristatin E, in patients with HER2-positive locally advanced or metastatic urothelial carcinoma (UC) refractory to standard or regular therapies. PATIENTS AND METHODS: The data analyzed and reported are from two phase II, open-label, multicenter, single-arm studies (RC48-C005 and RC48-C009) in patients with HER2-positive (immunohistochemistry 3+ or 2+) locally advanced or metastatic UC who have progressed on at least one previous line of systemic chemotherapy...
November 21, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37988644/assessing-predictability-of-pathologic-lymph-node-regression-for-recurrence-and-survival-in-esophageal-adenocarcinoma
#9
LETTER
Ryan Sun, Jingyi Liu, Lee-Jen Wei
No abstract text is available yet for this article.
November 21, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37988643/reply-to-r-sun-et-al
#10
JOURNAL ARTICLE
Jonathan L Moore, Aida Santaolalla, Mieke Van Hemelrijck, Bernard North, Andrew R Davies
No abstract text is available yet for this article.
November 21, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37988638/selective-personalized-radioimmunotherapy-for-locally-advanced-non-small-cell-lung-cancer-trial
#11
JOURNAL ARTICLE
Nitin Ohri, Shruti Jolly, Benjamin T Cooper, Rafi Kabarriti, William R Bodner, Jonathan Klein, Chandan Guha, Shankar Viswanathan, Elaine Shum, Joshua K Sabari, Haiying Cheng, Rasim A Gucalp, Enrico Castellucci, Angel Qin, Shirish M Gadgeel, Balazs Halmos
PURPOSE: Standard therapy for locally advanced non-small-cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. For biomarker-selected patients with LA-NSCLC, we hypothesized that sequential pembrolizumab and risk-adapted radiotherapy, without chemotherapy, would be well-tolerated and effective. METHODS: Patients with stage III NSCLC or unresectable stage II NSCLC and an Eastern Cooperative Oncology Group performance status of 0-1 were eligible for this trial...
November 21, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37983585/burden-of-morbidity-and-mortality-in-adolescent-and-young-adult-cancer-survivors
#12
REVIEW
Saro H Armenian, Chun Chao
There are an estimated 650,00 survivors of adolescent and young adult (AYA) cancers in the United States, a number that is expected to markedly increase in the coming decades. The recognition of the potential for some cancer treatments to affect the health of patients for many years after the initial diagnosis has prompted investigators to examine the evolving burden of late morbidity and mortality in AYAs with cancer after treatment completion. Studies in large international cohorts of AYA cancer survivors have now shown that the burden of late effects in survivors treated during the past four decades is substantial, affecting the health and well-being of the survivor, health systems' preparedness to meet their health care needs in the future, and societal economic costs that are largely affected by loss of productivity...
November 20, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37983570/classic-hodgkin-lymphoma-in-adolescents-and-young-adults
#13
REVIEW
Kara M Kelly, Jonathan W Friedberg
Hodgkin lymphoma (HL) represents one of the more common cancers occurring in adolescent and young adults (AYAs) age 15-39 years. Despite a generally high cure rate, age-related differences in HL biology and the optimal therapeutic approaches including supportive care and risks for long-term adverse effects in the AYA population remain understudied. After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches. Recently completed and ongoing studies will foster harmonization of risk group definition and trial eligibility criteria across the AYA spectrum, enabling more rapid progress...
November 20, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37978951/everolimus-for-children-with-recurrent-or-progressive-low-grade-glioma-results-from-the-phase-ii-pnoc001-trial
#14
JOURNAL ARTICLE
Daphne A Haas-Kogan, Mariam S Aboian, Jane E Minturn, Sarah E S Leary, Mohamed S Abdelbaki, Stewart Goldman, Jennifer D Elster, Adam Kraya, Matthew R Lueder, Divya Ramakrishnan, Marc von Reppert, Kevin X Liu, Jo Lynne Rokita, Adam C Resnick, David A Solomon, Joanna J Phillips, Michael Prados, Annette M Molinaro, Sebastian M Waszak, Sabine Mueller
PURPOSE: The PNOC001 phase II single-arm trial sought to estimate progression-free survival (PFS) associated with everolimus therapy for progressive/recurrent pediatric low-grade glioma (pLGG) on the basis of phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway activation as measured by phosphorylated-ribosomal protein S6 and to identify prognostic and predictive biomarkers. PATIENTS AND METHODS: Patients, age 3-21 years, with progressive/recurrent pLGG received everolimus orally, 5 mg/m2 once daily...
November 17, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37976452/fertility-preservation-in-adolescents-and-young-adults-with-cancer-a-case-based-review
#15
REVIEW
Karen Burns, Alison W Loren
Adolescent and young adult (AYA) oncology patients are unique in many aspects of their care; fertility preservation (FP) is one of the most complex to address. In addition to the newly diagnosed AYA patient, there are growing numbers of AYA survivors of childhood cancer who present with concerns about their fertility. Emerging independence, emotional and intellectual growth, and development of an adult mindset are hallmarks of the AYA population; these transitions heighten the intrinsic medical, social, and financial challenges of a cancer diagnosis...
November 17, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37976444/skyscraper-02-tiragolumab-in-combination-with-atezolizumab-plus-chemotherapy-in-untreated-extensive-stage-small-cell-lung-cancer
#16
JOURNAL ARTICLE
Charles M Rudin, Stephen V Liu, Ross A Soo, Shun Lu, Min Hee Hong, Jong-Seok Lee, Maciej Bryl, Daphne W Dumoulin, Achim Rittmeyer, Chao-Hua Chiu, Ozgur Ozyilkan, Melissa Johnson, Alejandro Navarro, Silvia Novello, Yuichi Ozawa, Sammi Hiu Tam, Namrata S Patil, Xiaohui Wen, Meilin Huang, Tien Hoang, Raymond Meng, Martin Reck
PURPOSE: The phase III SKYSCRAPER-02 study determined whether the benefits of atezolizumab plus carboplatin and etoposide (CE) could be enhanced by the addition of tiragolumab in untreated extensive-stage small-cell lung cancer (ES-SCLC). We report final progression-free survival (PFS) and overall survival (OS) analyses. METHODS: Patients received tiragolumab 600 mg/placebo, plus atezolizumab 1,200 mg and CE (four cycles), then maintenance tiragolumab/placebo plus atezolizumab...
November 17, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37976443/extending-the-breast-cancer-surveillance-consortium-model-of-invasive-breast-cancer
#17
JOURNAL ARTICLE
Charlotte C Gard, Jeffrey A Tice, Diana L Miglioretti, Brian L Sprague, Michael C S Bissell, Louise M Henderson, Karla Kerlikowske
PURPOSE: We extended the Breast Cancer Surveillance Consortium (BCSC) version 2 (v2) model of invasive breast cancer risk to include BMI, extended family history of breast cancer, and age at first live birth (version 3 [v3]) to better inform appropriate breast cancer prevention therapies and risk-based screening. METHODS: We used Cox proportional hazards regression to estimate the age- and race- and ethnicity-specific relative hazards for family history of breast cancer, breast density, history of benign breast biopsy, BMI, and age at first live birth for invasive breast cancer in the BCSC cohort...
November 17, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37972346/clinical-validation-of-human-papilloma-virus-circulating-tumor-dna-for-early-detection-of-residual-disease-after-chemoradiation-in-cervical-cancer
#18
JOURNAL ARTICLE
Kathy Han, Jinfeng Zou, Zhen Zhao, Zeynep Baskurt, Yangqiao Zheng, Elizabeth Barnes, Jennifer Croke, Sarah E Ferguson, Anthony Fyles, Lilian Gien, Adam Gladwish, Magali Lecavalier-Barsoum, Stephanie L'heureux, Jelena Lukovic, Helen Mackay, Eve-Lyne Marchand, Ur Metser, Michael Milosevic, Amandeep S Taggar, Scott V Bratman, Eric Leung
PURPOSE: Most cervical cancers are caused by human papilloma virus (HPV), and HPV circulating tumor DNA (ctDNA) may identify patients at highest risk of relapse. Our pilot study using digital polymerase chain reaction (dPCR) showed that detectable HPV ctDNA at the end of chemoradiation (CRT) is associated with inferior progression-free survival (PFS) and that a next-generation sequencing approach (HPV-seq) may outperform dPCR. We aimed to prospectively validate HPV ctDNA as a tool for early detection of residual disease...
November 16, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37972345/reply-to-y-n-feng-et-al
#19
JOURNAL ARTICLE
Hielke M de Vries, Oscar R Brouwer, Eva Schaake, Michiel S van der Heijden
No abstract text is available yet for this article.
November 16, 2023: Journal of Clinical Oncology
https://read.qxmd.com/read/37972343/myths-and-presumptions-about-cancer-survivorship
#20
JOURNAL ARTICLE
Michael Halpern, Michelle A Mollica, Paul K J Han, Emily S Tonorezos
No abstract text is available yet for this article.
November 16, 2023: Journal of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.